Bortezomib influences the expression of malignant plasma cells membrane antigens

European Journal of Pharmacology

Volumn 706, Issue 1-3, 2013, Pages 11-16

  Tagoug, Ines ^a,b,c   Plesa, Adriana ^a,b,c   Dumontet, Charles ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Bortezomib; IGF 1R; Multiple myeloma; Syndecan 1

Indexed keywords

BORTEZOMIB; CD221 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 6; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE ANTIGEN; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; SOMATOMEDIN C; STAT PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIGENS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MEMBRANE PROTEINS; MICE; MICE, SCID; MULTIPLE MYELOMA; PLASMA CELLS; PROTEASOME INHIBITORS; PYRAZINES; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84875408309     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.02.002     Document Type: Article

References (24)

1. J. Adams, V.J. Palombella, E.A. Sausville, J. Johnson, A. Destree, D.D. Lazarus, J. Maas, C.S. Pien, S. Prakash, and P.J. Elliott Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res. 59 1999 2615 2622
2. H. Akiba, H. Nakano, S. Nishinaka, M. Shindo, T. Kobata, M. Atsuta, C. Morimoto, C.F. Ware, N.L. Malinin, D. Wallach, H. Yagita, and K. Okumura CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase J. Biol. Chem. 273 1998 13353 13358
3. J. Almeida, A. Orfao, M. Ocqueteau, G. Mateo, M. Corral, M.D. Caballero, J. Blade, M.J. Moro, J. Hernandez, and J.F. San Miguel High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma B. J. Haematol. 107 1999 121 131
4. K.C. Anderson Bortezomib therapy for myeloma Curr. Hematol. Rep. 3 2004 65
5. D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K.C. Anderson Proteasome inhibitor therapy in multiple myeloma Mol. Cancer Ther. 4 2005 686 692
6. J. De Vos, D. Hose, T. Reme, K. Tarte, J. Moreaux, K. Mahtouk, M. Jourdan, H. Goldschmidt, J.F. Rossi, F.W. Cremer, and B. Klein Microarray-based understanding of normal and malignant plasma cells Immunol. Rev. 210 2006 86 104
7. G. Descamps, P. Gomez-Bougie, C. Venot, P. Moreau, R. Bataille, and M. Amiot A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45 B. J. Cancer 100 2009 366 369
8. G. Descamps, C. Pellat-Deceunynck, Y. Szpak, R. Bataille, N. Robillard, and M. Amiot The magnitude of Akt/phosphatidylinositol 3′-kinase proliferating signaling is related to CD45 expression in human myeloma cells J. Immunol. 173 2004 4953 4959
9. M.V. Dhodapkar, E. Abe, A. Theus, M. Lacy, J.K. Langford, B. Barlogie, and R.D. Sanderson Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation Blood 91 1998 2679 2688
10. Y.Q. Guo, and S.L. Chen The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression Zhonghua Xue Ye Xue Za Zhi 27 2006 231 234
11. T. Hideshima, P. Richardson, D. Chauhan, V.J. Palombella, P.J. Elliott, J. Adams, and K.C. Anderson The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res. 61 2001 3071 3076
12. S. Kumar, S.V. Rajkumar, T. Kimlinger, P.R. Greipp, and T.E. Witzig CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations Leukemia 19 2005 1466 1470
13. E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, and K. Vanderkerken Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model Blood 107 2006 655 660
14. C.S. Mitsiades, N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama, D. Chauhan, T. Hideshima, S.P. Treon, N.C. Munshi, P.G. Richardson, and K.C. Anderson Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications Oncogene 21 2002 5673 5683
15. E.A. Obeng, L.M. Carlson, D.M. Gutman, W.J. Harrington Jr., K.P. Lee, and L.H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 2006 4907 4916
16. C. Pellat-Deceunynck, and R. Bataille Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression Blood Cells, Mol. Dis. 32 2004 293 301
17. A.C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R.A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, L. Kovarova, M. Lioznov, G. Mateo, R. Morilla, A.K. Mylin, P. Omede, C. Pellat-Deceunynck, M. Perez Andres, M. Petrucci, M. Ruggeri, G. Rymkiewicz, A. Schmitz, M. Schreder, C. Seynaeve, M. Spacek, R.M. de Tute, E. Van Valckenborgh, N. Weston-Bell, R.G. Owen, J.F. San Miguel, P. Sonneveld, and H.E. Johnsen Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Haematologica 93 2008 431 438
18. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, D. Siegel, R.Z. Orlowski, D. Kuter, S.A. Limentani, S. Lee, T. Hideshima, D.L. Esseltine, M. Kauffman, J. Adams, D.P. Schenkein, and K.C. Anderson A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 348 2003 2609 2617
19. P.G. Richardson, C. Mitsiades, T. Hideshima, and K.C. Anderson Proteasome inhibition in the treatment of cancer Cell Cycle 4 2005 290 296
20. Tagoug, I., Sauty De Chalon, A., Dumontet, C., Inhibition of IGF-1 signalling enhances the apoptotic effect of As602868, an Ikk2 inhibitor, in multiple myeloma cell lines. PloS One 6, 2011, e22641.
21. Y.T. Tai, K. Podar, L. Catley, Y.H. Tseng, M. Akiyama, R. Shringarpure, R. Burger, T. Hideshima, D. Chauhan, N. Mitsiades, P. Richardson, N.C. Munshi, C.R. Kahn, C. Mitsiades, and K.C. Anderson Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling Cancer Res. 63 2003 5850 5858
22. I.S. Trowbridge, and M.L. Thomas CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development Annu. Rev. Immunol. 12 1994 85 116
23. M.C. Wang, X.D. Fu, and M.X. Li PI-3K/Akt/GSK-3beta signaling cascades stimulated by insulin like growth factor-I contribute to multiple myeloma cells proliferation and survival Chin. Med. J. 119 2006 1226 1229
24. H. Yamamoto, T. Kishimoto, and S. Minamoto NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27 J. Immunol. 161 1998 4753 4759